ACVIM consensus statement guidelines for the diagnosis, classification, treatment, and monitoring of pulmonary hypertension in dogs. (17th February 2020)

• Record Type: Journal Article
• Authors: Reinero, Carol; Visser, Lance C.; Kellihan, Heidi B.; Masseau, Isabelle; Rozanski, Elizabeth; Clercx, Cécile; Williams, Kurt; Abbott, Jonathan; Borgarelli, Michele; Scansen, Brian A.
• Is Part Of: Journal of veterinary internal medicine. Volume 34:Number 2(2020)
• Page Start: 549
• Page End: 573
• Publication Date: 2020-02-17
• Subjects: echocardiography -- pulmonary arterial hypertension -- respiratory disease -- tricuspid regurgitation velocity; Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.15725
• Languages: English
• ISSNs: 0891-6640

Abstract

Abstract: Pulmonary hypertension (PH), defined by increased pressure within the pulmonary vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of cardiovascular, respiratory, and systemic diseases. The purpose of this consensus statement is to provide a multidisciplinary approach to guidelines for the diagnosis, classification, treatment, and monitoring of PH in dogs. Comprehensive evaluation including consideration of signalment, clinical signs, echocardiographic parameters, and results of other diagnostic tests supports the diagnosis of PH and allows identification of associated underlying conditions. Dogs with PH can be classified into the following 6 groups: group 1, pulmonary arterial hypertension; group 2, left heart disease; group 3, respiratory disease/hypoxia; group 4, pulmonary emboli/pulmonary thrombi/pulmonary thromboemboli; group 5, parasitic disease ( Dirofilaria and Angiostrongylus ); and group 6, disorders that are multifactorial or with unclear mechanisms. The approach to treatment of PH focuses on strategies to decrease the risk of progression, complications, or both, recommendations to target underlying diseases or factors contributing to PH, and PH‐specific treatments. Dogs with PH should be monitored for improvement, static condition, or progression, and any identified underlying disorder should be addressed and monitored simultaneously.